

**Supplementary table (1): comparison between the two study groups regarding age and gender.**

Characteristics	Group A (N=23)	Group B (N=25)	P-value
<b>Age (year)</b>			
Mean± S.D.	11.17 ± 1.72	11.4 ± 1.89	0.668*
Median (IQ range)	11 (10 – 12)	12 (10 – 13)	
<b>Gender</b>			1
Female	1 (4.35%)	1 (4%)	
Male	22 (95.65%)	24 (96%)	

P-value was calculated by Fisher's Exact Test

\*P-value was calculated by Independent Samples Test

**Supplementary table (2): comparison between the two study groups regarding preoperative measures.**

Characteristics	Group A (N=23)	Group B (N=25)	P-value
<b>BCVA (Log MAR)</b>			
Mean± S.D.	0.52 ± 0.12	0.53 ± 0.12	0.924*
Median (IQ range)	0.5 (0.4 – 0.6)	0.5 (0.4 – 0.6)	
<b>AC cells</b>			0.812
1	2 (8.7%)	2 (8%)	
2	18 (78.26%)	18 (72%)	
3	3 (13.04%)	5 (20%)	
<b>AC nodules</b>			0.559
1	19 (82.61%)	21 (84%)	
2	4 (17.39%)	3 (12%)	
3	0 (0.0%)	1 (4%)	

P-value was calculated by Chi-Square test

\*P-value was calculated by Mann-Whitney U test

**Supplementary table (3): comparison between the two study groups regarding two weeks postoperative measures.**

Characteristics	Group A (N=23)	Group B (N=25)	P-value
<b>BCVA (Log MAR)</b>			
Mean± S.D.	<b>0.22 ± 0.1</b>	<b>0.24 ± 0.1</b>	0.683*
Median (IQ range)	<b>0.2 (0.2 – 0.3)</b>	<b>0.2 (0.15 – 0.3)</b>	
<b>AC cells</b>			0.408
0	<b>3 (13.04%)</b>	<b>3 (12%)</b>	
0.5	<b>11 (47.83%)</b>	<b>7 (28%)</b>	
1	<b>9 (39.13%)</b>	<b>14 (56%)</b>	
2	<b>0 (0.0%)</b>	<b>1 (4%)</b>	
<b>Granuloma</b>			0.653
Disappeared	<b>17 (73.91%)</b>	<b>17 (68%)</b>	
Persistent	<b>6 (26.09%)</b>	<b>8 (32%)</b>	

P-value was calculated by Chi-Square test

\*P-value was calculated by Mann-Whitney U test

**Supplementary table (4): comparison between the two study groups regarding one-month postoperative measures.**

Characteristics	Group A (N=23)	Group B (N=25)	P-value
<b>BCVA (Log MAR)</b>			
Mean± S.D.	<b>0.11 ± 0.08</b>	<b>0.1 ± 0.07</b>	0.752*
Median (IQ range)	<b>0.1 (0.1 – 0.2)</b>	<b>0.1 (0.1 – 0.15)</b>	
<b>AC cells</b>			0.486
0	<b>20 (86.96%)</b>	<b>19 (76%)</b>	
0.5	<b>3 (13.04%)</b>	<b>5 (20%)</b>	
1	<b>0 (0.0%)</b>	<b>1 (4%)</b>	
<b>Granuloma</b>			1**
Disappeared	<b>22 (95.65%)</b>	<b>23 (92%)</b>	
Persistent	<b>1 (4.35%)</b>	<b>2 (8%)</b>	

P-value was calculated by Chi-Square test

\*P-value was calculated by Mann-Whitney U test

\*\*P-value was calculated by Fisher's Exact Test

**Supplementary table (5): comparison between the two study groups regarding three months postoperative measures.**

Characteristics	Group A (N=23)	Group B (N=25)	P-value
<b>BCVA (Log MAR)</b>			
<b>Mean± S.D.</b>	<b>0.06 ± 0.08</b>	<b>0.16 ± 0.17</b>	0.074*
<b>Median (IQ range)</b>	<b>0 (0 – 0.1)</b>	<b>0.1 (0 – 0.3)</b>	
<b>AC cells</b>			0.078
<b>0</b>	<b>19 (82.6%)</b>	<b>13 (52%)</b>	
<b>0.5</b>	<b>2 (8.7%)</b>	<b>5 (20%)</b>	
<b>1</b>	<b>2 (8.7%)</b>	<b>7 (28%)</b>	
<b>Granuloma</b>			<b>0.002</b>
<b>Disappeared</b>	<b>22 (95.65%)</b>	<b>14 (56%)</b>	
<b>Persistent</b>	<b>1 (4.35%)</b>	<b>11 (44%)</b>	

P-value was calculated by Chi-Square test

\*P-value was calculated by Mann-Whitney U test

P-value < 0.05 is statistically significant

**Supplementary table (6): comparison between the repeated BCVA (Log MAR) measures.**

	BCVA (Log MAR)				P-value
	Pre-operative	Two weeks post-operative	One-month post-operative	Three months post-operative	
<b>Group A</b>					
Mean± S.D.	<b>0.52 ± 0.12</b>	<b>0.22 ± 0.1</b>	<b>0.11 ± 0.08</b>	<b>0.06 ± 0.08</b>	<b>&lt;0.001</b>
Median (IQ range)	<b>0.5 (0.4 – 0.6)</b>	<b>0.2 (0.2 – 0.3)</b>	<b>0.1 (0.1 – 0.2)</b>	<b>0 (0 – 0.1)</b>	
<b>Group B</b>					
Mean± S.D.	<b>0.53 ± 0.12</b>	<b>0.24 ± 0.1</b>	<b>0.1 ± 0.07</b>	<b>0.16 ± 0.17</b>	<b>&lt;0.001</b>
Median (IQ range)	<b>0.5 (0.4 – 0.6)</b>	<b>0.2 (0.15 – 0.3)</b>	<b>0.1 (0.1 – 0.15)</b>	<b>0.1 (0 – 0.3)</b>	

P-value was calculated by Friedman test

P-value < 0.05 is statistically significant

Supplementary table (7): comparison between the repeated AC cells examinations.

Characteristics	AC cells				P-value
	Pre-operative	Two weeks post-operative	One-month post-operative	Three months post-operative	
<b>Group A</b>					
<b>0</b>	<b>0 (0.0%)</b>	<b>3 (13.04%)</b>	<b>20 (86.96%)</b>	<b>19 (82.6%)</b>	<b>&lt;0.001</b>
<b>0.5</b>	<b>0 (0.0%)</b>	<b>11 (47.83%)</b>	<b>3 (13.04%)</b>	<b>2 (8.7%)</b>	
<b>1</b>	<b>2 (8.7%)</b>	<b>9 (39.13%)</b>	<b>0 (0.0%)</b>	<b>2 (8.7%)</b>	
<b>2</b>	<b>18 (78.26%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	
<b>3</b>	<b>3 (13.04%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	
<b>Group B</b>					
<b>0</b>	<b>0 (0.0%)</b>	<b>3 (12%)</b>	<b>19 (76%)</b>	<b>13 (52%)</b>	<b>&lt;0.001</b>
<b>0.5</b>	<b>0 (0.0%)</b>	<b>7 (28%)</b>	<b>5 (20%)</b>	<b>5 (20%)</b>	
<b>1</b>	<b>2 (8%)</b>	<b>14 (56%)</b>	<b>1 (4%)</b>	<b>7 (28%)</b>	
<b>2</b>	<b>18 (72%)</b>	<b>1 (4%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	
<b>3</b>	<b>5 (20%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	<b>0 (0.0%)</b>	

P-value was calculated by Friedman test

P-value < 0.05 is statistically significant

**Supplementary table (8): comparison between the repeated Granuloma examinations.**

Characteristics	Granuloma			P-value
	Two weeks post-operative	One-month post-operative	Three months post-operative	
<b>Group A</b>				
<b>Disappeared</b>	<b>17 (73.91%)</b>	<b>22 (95.65%)</b>	<b>22 (95.65%)</b>	<b>0.007</b>
<b>Persistent</b>	<b>6 (26.09%)</b>	<b>1 (4.35%)</b>	<b>1 (4.35%)</b>	
<b>Group B</b>				
<b>Disappeared</b>	<b>17 (68%)</b>	<b>23 (92%)</b>	<b>14 (56%)</b>	<b>0.001</b>
<b>Persistent</b>	<b>8 (32%)</b>	<b>2 (8%)</b>	<b>11 (44%)</b>	

P-value was calculated by Cochran's Q test

P-value < 0.05 is statistically significant.

